Navigation Links
Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Date:7/20/2009

AIEA, Hawaii, July 20 /PRNewswire/ -- The Centers for Disease Control and Prevention reported this week that the prevalence of obesity among Americans is now over 26%. Obesity exacerbates a constellation of diseases including diabetes, liver disease, and heart disease, often in the same patient, and is referred to as "metabolic syndrome." Low level inflammation and oxidative stress are the mechanistic underpinnings of metabolic syndrome.

The Cardax lead compound is a novel and highly bioavailable proprietary derivative of the natural dietary carotenoid astaxanthin that addresses metabolic syndrome, including liver and cardiovascular disease as well as diabetes. Preclinical animal studies with the Company's compounds or its active metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels indicative of liver damage, such as ALT and AST, are decreased, pointing to an outstanding safety profile. Increases in HDL, the "good" cholesterol and increased insulin sensitivity have also been documented along with a robust improvement in thrombosis and myocardial salvage.

The Cardax drug reduces systemic inflammation and oxidative stress while localizing in the liver and the vasculature. Cellular studies have determined that this compound acts as a plasma and mitochondrial membrane stabilizer and a potent antioxidant.

"Cardax has pioneered a novel approach to treating the source of inflammation, intracellular oxidative stress," said David G. Watumull, CEO of Cardax. "We believe this to be a new paradigm for the treatment of liver and cardiovascular disease as well as metabolic syndrome."

"Our novel derivative of the natural carotenoid astaxanthin exhibits dramatically improved bioavailability relative to the parent compound," adds Chief Medical Officer, Fred Pashkow, M.D. "Our drug enables the oral bioavailability and dose control required for clinical study and it is converted to the natural active metabolite in the gastrointestinal tract. It effectively combines the properties of an efficacious pharmaceutical with the safety of a natural dietary carotenoid."

About Cardax Pharmaceuticals. Cardax Pharmaceuticals is developing a platform of proprietary, exceptionally safe, small molecule compounds that impact inflammation driven by mitochondrial oxidative stress. The Company's first product localizes intracellularly in heart and liver tissue, including mitochondria, and is in pre-clinical development for cardiovascular and liver disease indications. Cardax Pharmaceuticals was spun out from Hawaii Biotech in May 2006. Cardax Pharmaceuticals is a privately held biopharmaceutical company developing safer, more effective treatments for diseases driven by inflammation and oxidative stress, including liver disease, cardiovascular disease, and macular degeneration. For further information, please contact us at (808) 457-1375 or visit http://www.cardaxpharma.com

    Contact:
    David G. Watumull
    President and CEO
    (808) 457-1375
    dwatumull@cardaxpharma.com


'/>"/>
SOURCE Cardax Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
2. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
5. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
6. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
7. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
10. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
11. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- The Global Therapy Partnering Terms and Agreements since ... and agreements entered into by the world,s leading healthcare ... deals by value - Deals listed by company A-Z, ... report provides understanding and access to the partnering deals ... companies. The report provides an analysis of partnering ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
(Date:1/19/2017)... Jan. 18, 2017 The Academy of ... Drug Administration (FDA) for its release today of ... health decision makers can proactively share clinical and ... well as emerging therapies awaiting FDA approval. ... recommendations that AMCP developed during two multi-stakeholder meetings ...
Breaking Medicine Technology:
(Date:1/20/2017)... Raton, FL (PRWEB) , ... January 20, 2017 ... ... nutritional and wellness products to enhance people’s everyday lives, recently attended the January ... retail buyers. , ATP Science is known for its large range of supplements ...
(Date:1/20/2017)... ... ... Magdalene: Grace is Greater than Sin”: a unique and memorable piece of literature ... Grace is Greater than Sin” is the creation of published author, Brenda Roberts, a ... had little knowledge of the female characters portrayed in the Holy Bible. , ...
(Date:1/20/2017)... ... 2017 , ... “Christmas in Suffolk”: a story of love, secrets, and ... in Lafayette, Indiana where she works in a daycare and looks for inspiration in ... by Christian Faith Publishing, Sara Seymour’s new book is an adventure of love and ...
(Date:1/19/2017)... ... 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced ... Models (APMs) in 2017. Clinicians who participate in APMs are paid for the quality ... the Administration’s effort to build a system that delivers better care and one in ...
(Date:1/19/2017)... Florida (PRWEB) , ... January 19, 2017 , ... This ... LCSW, announced that the name of their drug rehab center in Delray Beach, Florida ... we recognize that not only stars such as Philip Seymour Hoffman and Chris Farley ...
Breaking Medicine News(10 mins):